drugset / Trial / NCT00992537

Comparison of the Effect of NN5401 With the Effect of NN1250 and Insulin Aspart in Type 1 Diabetics

NCT00992537

Phase 1 Completed 27 enrolled Novo Nordisk A/S
RandomizedCrossoverOpen-labelTreatment

Summary

This trial is conducted in Europe. The aim of this clinical trial is to compare the blood glucose lowering effect of NN5401(insulin degludec/insulin aspart (IDegAsp)) with NN1250 (insulin degludec (IDeg)) and insulin aspart (IAsp) in subjects with type 1 diabetes where the trial participant will receive one single dose of each trial product in varying order.

Timeline

Start
2009-10
Primary completion
2010-01
Completion
2010-01

Drugs

EvaluationDrugModalityDoseRoute
Comparator insulin aspart Protein / enzyme biologic 0.5 iu/kg Subcutaneous
Subject insulin degludec Protein / enzyme biologic 0.5 iu/kg Subcutaneous
Subject insulin degludec/insulin aspart Unknown 0.5 iu/kg Subcutaneous